<DOC>
	<DOC>NCT01193296</DOC>
	<brief_summary>The study will assess glycemic variability and optimized glycemic control in T2DM patients treated with a DPP-4 inhibitor as add-on therapy to metformin.</brief_summary>
	<brief_title>Glycemic Holter Study (Continuous Glucose Monitoring) -</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 Diabetes Mellitus (DM) willing to perform SMBG at least 6 times daily to use the MiniMed CGMS for up to 3 consecutive days on 2 occasions. HbA1c: 6.5 to 9% with metformin monotherapy for a least 3 months Age &gt;= 80 years BMI &lt;= 22 and &gt;=40 kg/m2 Secondary T2 DM Hepatic failure, ASAT/ALAT&gt;3 ULN, and moderate/severe renal failure (CI &lt; 50 ml/min) CHF III &amp; IV Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Diabetes mellitus, vildagliptin, continuous glucose monitoring</keyword>
</DOC>